VANESSA GREEN: Open Payments
NPI 1023850930 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 32 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $158 · 2025 $1,022
Food & beverage: $752Education: $270
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $222 |
| Daiichi Sankyo Inc. | 4 | $179 |
| Incyte Corporation | 2 | $109 |
| ABBVIE INC. | 3 | $67 |
| GENZYME CORPORATION | 1 | $37 |
| Novartis Pharmaceuticals Corporation | 1 | $34 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| SpringWorks Therapeutics, Inc. | 1 | $29 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
Products named: Enhertu, RYBREVANT, ERLEADA, AYVAKIT, KISQALI, OPDIVO, EMRELIS, OGSIVEO.
Industry payments across CA — which companies pay providers there.
